Mate I could not agree more - but its not happening so far.
You would think after the P3 trial success you would seek to promote and highlight the impending FDA decision. Then post FDA, you would think you would further promote the wonderful outcome and groundbreaking decision. Then after ROW, which includes Australia, you would think you would return to promote it again and raise awareness of the drug and how it is possible that Neuren could tackle Autism etc etc.
But crickets....at least from a public, non-investing perspective.
I think the company needs to do more than just appeal to institutional investors.
I know people who barely ever invest in shares and they know about Mesoblast because it got proper media attention a while back. They have not heard of Neuren.
- Forums
- ASX - By Stock
- NEU
- Share Price
Share Price, page-6206
-
- There are more pages in this discussion • 4,661 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.45 |
Change
-0.070(0.34%) |
Mkt cap ! $2.613B |
Open | High | Low | Value | Volume |
$20.60 | $20.77 | $20.32 | $3.866M | 188.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 237 | $20.44 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.49 | 1026 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2633 | 20.380 |
3 | 1467 | 20.360 |
1 | 1033 | 20.350 |
2 | 1853 | 20.340 |
1 | 828 | 20.320 |
Price($) | Vol. | No. |
---|---|---|
20.490 | 1026 | 2 |
20.550 | 2289 | 3 |
20.560 | 639 | 2 |
20.570 | 631 | 3 |
20.590 | 828 | 1 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online